Evotec Shares Face Critical Test Ahead of Earnings Release

Evotec's 2025 results on April 8 highlight a split: core drug discovery struggles while biologics booms. Analysts are divided on its Horizon restructuring plan.

Investors are bracing for a pivotal moment as Evotec SE prepares to announce its final results for the 2025 fiscal year on April 8. The Hamburg-based biotechnology firm finds itself at a crossroads, caught between a contracting core business and strategic initiatives designed to secure its future. This tension is evident in the sharply divided opinions among market analysts.

Diverging Business Segments Create a Mixed Picture

The company's recent weak guidance for the current year is a primary concern for the market. For 2026, management has projected an adjusted EBITDA of only €0 to €40 million, a figure that fell significantly short of analyst expectations, which were north of €80 million. Consequently, Evotec has framed 2026 as a transitional period.

This pressure stems largely from the performance of its core drug discovery operations. Revenue in this segment declined by 13% in 2025, pushing its segment EBITDA into negative territory. In stark contrast, the Just Evotec Biologics division demonstrated robust growth, with revenue increasing approximately 40% to €259 million, providing crucial support to the group's overall financials. Furthermore, the pending sale of its biologics site in Toulouse to Sandoz, a transaction with a potential value exceeding $650 million, is set to offer a substantial financial cushion for the company's ongoing strategic shift.

Wall Street's Verdict: A Spectrum of Opinions

In response to these challenges, Evotec is aggressively pursuing its "Horizon" restructuring plan. The program, which involves cutting up to 800 jobs and reducing its global sites from 14 to 10, is targeted to generate annual savings of €75 million from 2027 onward. These future benefits come at an upfront cost, however, with one-time restructuring charges estimated at around €100 million.

The market's assessment of this blend of a shrinking core and an ambitious transformation is far from unanimous, as reflected in recent analyst notes:

• RBC Capital Markets maintains an "Outperform" rating with a price target of €10.00.
• Berenberg has lowered its target to €9.70 but continues to recommend a "Buy."
• Deutsche Bank has taken a more cautious stance, significantly reducing its price target from €6.00 to €4.50 and keeping a "Hold" rating.

The skepticism voiced by Deutsche Bank aligns with recent trading activity. The stock, currently trading around €4.52, sits nearly 46% below its 52-week high reached in May of last year.

The upcoming earnings report on April 8 is now seen as a critical opportunity for management to provide concrete evidence that the "Horizon" cost-saving measures are taking hold. For the medium term, the leadership reaffirms its targets: Group revenue is expected to surpass the €1 billion mark by 2030, coupled with an operational margin of 20% by 2028. The company anticipates the first positive effects from its restructuring efforts to materialize in the second half of 2026.